If you have been reading about cyclic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
== Realism and balancing == The balance of power theory is a core tenet of both classical and neorealist theory and seeks to explain alliance formation. Due to the neorealist idea of anarchism as a result of the international system, states must ensure their survival through maintaining or increasing their power in a self-help world. With no authority above the state to come to its rescue in the event of an attack by a hegemon, states attempt to prevent a potential hegemon from arising by balancing against it. According to Kenneth Waltz, founder of neorealism, "balance-of-power politics prevail wherever two, and only two requirements are met: that the order be anarchic and that it be populated by units wishing to survive". They can do this either through "internal balancing", where a state uses internal efforts such as moving to increase economic capability, developing clever strategies and increasing military strength, or through "external balancing", which occurs when states take external measures to increase their security by forming allies. As states are assumed to be skeptical of the intentions of other states, neorealists primarily hold that states balance through "self-help", as they expand their military capabilities and copy military innovations of competitors. States happy with their place in the system are known as "status quo" states, while those seeking to alter the balance of power in their favor are generally referred to as "revisionist states" and aspire for hegemony, thus repairing the balance.
While in graduate school in the 1960s she began working on corticotropin, and while trying to purify this hormone later in her career she made a chance finding of a peptide called substance P. This event subsequently led to her life's work of researching substance P and another peptide she chemically isolated and defined, neurotensin.
For example, the nitrile group of the competitive PDE-3 inhibitor milrinone forms an affinity-relevant hydrogen bond via a histidine residue located at the binding site of these phosphodiesterases. Nitriles can form a coordinative bond with calcium cations, which is essential for the activity of calcium antagonists of the verapamil type. These agents inhibit calcium influx by forming, through ligand–calcium complex chemistry, a salt bridge with one of the glutamic acid residues in the selectivity filter within the pore of the calcium channel. Verapamil is used in cardiovascular diseases such as arterial hypertension and angina pectoris. Nitrile substituents decrease the electron density of aromatic compounds through a strong inductive effect. In this manner, π-π interactions between a drug molecule and suitable amino acid residues of a target protein, such as phenylalanine, tyrosine, tryptophan, and histidine, are modulated. Such π-π interactions are observed with the aromatase inhibitors letrozole and anastrozole, which act as antiestrogens and are used in breast cancer. Many androgen receptor antagonists contain a markedly electron-deficient aromatic ring, which is particularly important for supramolecular receptor binding. In bicalutamide, enzalutamide, and other analogs used to treat prostate cancer, a nitrile group contributes to this electronic effect. In some cases, nitriles form a reversible yet pharmacologically relevant covalent bond with a target molecule.
Sources: en.wikipedia.org
== Examples == DNA-binding proteins include transcription factors which modulate the process of transcription, various polymerases, nucleases which cleave DNA molecules, and histones which are involved in chromosome packaging and transcription in the cell nucleus. DNA-binding proteins can incorporate such domains as the zinc finger, the helix-turn-helix, and the leucine zipper (among many others) that facilitate binding to nucleic acid. There are also more unusual examples such as transcription activator like effectors.
Almost every incumbent party worldwide facing election in 2024 lost vote share, including in South Africa, India, France, the United Kingdom, and Japan. Among democracies, over 80 percent saw the incumbent party lose support compared to the last election. This is the first time this has ever happened since 1905 (when data was first recorded) and the first time in the history of democracy, as universal suffrage began in 1894. All 50 states and the District of Columbia shifted rightward compared to 2020. Trump's gains in nearly all geographic areas and among nearly every demographic group provides strong evidence of anti-incumbent backlash. The shifts toward Trump were much less in the swing states where both campaigns focused compared to safe states. The two states with the largest shifts toward Trump, New York and New Jersey, were both won by Harris. Harris had very little room to fall in the swing states, given that Biden had won most of them by very small margins in 2020. Statistician and election analyst Nate Silver argued before the election that the national electoral environment was difficult for Democrats. This view was also shared by The New York Times political analyst Nate Cohn. After the election, Silver felt that Harris was a replacement-level candidate who did much better than Biden would have, but was unable to separate herself from Biden's record and was negatively perceived by swing voters due to her previous positions.
=== EC 1.14.11 With 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors === EC 1.14.11.1: γ-butyrobetaine dioxygenase EC 1.14.11.2: procollagen-proline dioxygenase EC 1.14.11.3: pyrimidine-deoxynucleoside 2′-dioxygenase EC 1.14.11.4: procollagen-lysine 5-dioxygenase EC 1.14.11.5: Now included with EC 1.14.11.6 thymine dioxygenase EC 1.14.11.6: thymine dioxygenase EC 1.14.11.7: procollagen-proline 3-dioxygenase EC 1.14.11.8: trimethyllysine dioxygenase EC 1.14.11.9: flavanone 3-dioxygenase EC 1.14.11.10: pyrimidine-deoxynucleoside 1′-dioxygenase EC 1.14.11.11: hyoscyamine (6S)-dioxygenase EC 1.14.11.12: gibberellin-44 dioxygenase EC 1.14.11.13: gibberellin 2β-dioxygenase EC 1.14.11.14: Now EC 1.14.20.13, 6β-hydroxyhyoscyamine epoxidase EC 1.14.11.15: gibberellin 3β-dioxygenase EC 1.14.11.16: peptide-aspartate β-dioxygenase EC 1.14.11.17: taurine dioxygenase EC 1.14.11.18: phytanoyl-CoA dioxygenase EC 1.14.11.19: Now EC 1.14.20.4, anthocyanidin synthase EC 1.14.11.20: deacetoxyvindoline 4-hydroxylase EC 1.14.11.21: clavaminate synthase EC 1.14.11.22: Now EC 1.14.20.5, flavone synthase EC 1.14.11.23: Now EC 1.14.20.6, flavonol synthase EC 1.14.11.24: 2′-deoxymugineic-acid 2′-dioxygenase EC 1.14.11.25: mugineic-acid 3-dioxygenase EC 1.14.11.26: deacetoxycephalosporin-C hydroxylase EC 1.14.11.27: [histone H3]-dimethyl-L-lysine36 demethylase EC 1.14.11.28: proline 3-hydroxylase EC 1.14.11.29: hypoxia-inducible factor-proline dioxygenase EC 1.14.11.30: hypoxia-inducible factor-asparagine dioxygenase EC 1.14.11.31: thebaine 6-O-demethylase EC 1.14.11.32: codeine 3-O-demethylase EC 1.14.11.33: DNA oxidative demethylase EC 1.14.11.34: Now EC 1.14.20.7, 2-oxoglutarate/L-arginine monooxygenase/decarboxylase (succinate-forming) EC 1.14.11.35: 1-deoxypentalenic acid 11β-hydroxylase EC 1.14.11.36: pentalenolactone F synthase EC 1.14.11.36: pentalenolactone F synthase EC 1.14.11.37: kanamycin B dioxygenase EC 1.14.11.38: verruculogen synthase EC 1.14.11.39: L-asparagine hydroxylase EC 1.14.11.40: enduracididine β-hydroxylase EC 1.14.11.41: L-arginine hydroxylase EC 1.14.11.42: tRNAPhe (7-(3-amino-3-carboxypropyl)wyosine37-C2)-hydroxylase EC 1.14.11.43: (S)-dichlorprop dioxygenase (2-oxoglutarate) EC 1.14.11.44: (R)-dichlorprop dioxygenase (2-oxoglutarate) EC 1.14.11.45: L-isoleucine 4-hydroxylase EC 1.14.11.46: 2-aminoethylphosphonate dioxygenase EC 1.14.11.47: [50S ribosomal protein L16]-arginine 3-hydroxylase EC 1.14.11.48: xanthine dioxygenase EC 1.14.11.49: uridine-5′-phosphate dioxygenase EC|1.14.11.50: Now EC 1.14.20.8, (–)-deoxypodophyllotoxin synthase EC 1.14.11.51: DNA N6-methyladenine demethylase EC 1.14.11.52: validamycin A dioxygenase EC 1.14.11.53: mRNA N6-methyladenine demethylase EC 1.14.11.54: mRNA N1-methyladenine demethylase EC 1.14.11.55: ectoine hydroxylase EC 1.14.11.56: L-proline cis-4-hydroxylase EC 1.14.11.57: L-proline trans-4-hydroxylase EC 1.14.11.58: ornithine lipid ester-linked acyl 2-hydroxylase EC 1.14.11.59: 2,4-dihydroxy-1,4-benzoxazin-3-one-glucoside dioxygenase EC 1.14.11.60: scopoletin 8-hydroxylase EC 1.14.11.61: feruloyl-CoA 6-hydroxylase EC 1.14.11.62: trans-4-coumaroyl-CoA 2-hydroxylase EC 1.14.11.63: peptidyl-lysine (3S)-dioxygenase EC 1.14.11.64: glutarate dioxygenase EC 1.14.11.65: [histone H3]-dimethyl-L-lysine9 demethylase EC 1.14.11.66: [histone H3]-trimethylL-lysine9 demethylase EC 1.14.11.67: [histone H3]-trimethyl-LL-lysine4 demethylase EC 1.14.11.68: [histone H3]-trimethyl-L-lysine27 demethylase EC 1.14.11.69: [histone H3]-trimethyl-L-lysine37 demethylase EC 1.14.11.70: 7-deoxycylindrospermopsin hydroxylase EC 1.14.11.71: methylphosphonate hydroxylase EC 1.14.11.72: [2-(trimethylamino)ethyl]phosphonate dioxygenase EC 1.14.11.73: [protein]-arginine 3-hydroxylase EC 1.14.11.74: L-isoleucine 31-dioxygenase EC 1.14.11.75: 31-hydroxy-L-isoleucine 4-dioxygenase EC 1.14.11.76: L-glutamate 3(R)-hydroxylase EC 1.14.11.77: alkyl sulfatase
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.